Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Hepion Pharmaceuticals Inc HEPA

Healthcare
Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of drug therapy for treatment of chronic liver diseases. The Company is developing a treatment for non-alcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC), and other chronic liver diseases. Its cyclophilin inhibitor, rencofilstat, is being developed to offer benefits to address... see more

Recent & Breaking News (NDAQ:HEPA)

DIAMOND Mouse Model is Latest in a String of Nonclinical Studies Confirming the Antifibrotic Effects of Hepion Pharmaceutical's Lead Drug, CRV431

GlobeNewswire March 23, 2021

Hepion Pharmaceuticals Announces Presentation and Panel Participation at the Benzinga Global Biotech Small Cap Conference

GlobeNewswire March 22, 2021

Hepion Pharmaceuticals to Present on CRV431 and AI-POW(TM) at NASH-TAG 2021

Accesswire March 11, 2021

Hepion Pharmaceuticals, Inc. Announces Closing of Public Offering

Accesswire February 18, 2021

Hepion Pharmaceuticals Announces Pricing of Public Offering

GlobeNewswire February 16, 2021

Hepion Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

Accesswire February 12, 2021

Former Novo Nordisk Executive, Dr. Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer

Accesswire February 10, 2021

Hepion Pharmaceuticals to Participate in BIO CEO & Investor Digital Conference

Accesswire February 9, 2021

Tiziana Life Sciences plc ("Tiziana" or the "Company") - Appointment of Director

GlobeNewswire February 5, 2021

Hepion Pharmaceuticals to Participate in Upcoming January Virtual Investor Conferences

Accesswire January 5, 2021

Hepion Pharmaceuticals Announces Positive Top Line Data for Low Dose CRV431 in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH

Accesswire December 29, 2020

Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation with Final Dose Cohort in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH

Accesswire December 29, 2020

Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 for COVID-19

Accesswire December 22, 2020

Hepion Pharmaceuticals Completes 75 mg CRV431 Dosing, Initiates 225 mg Dosing in Phase 2a 'AMBITION' Clinical Trial for NASH

Accesswire December 10, 2020

Hepion Pharmaceuticals' CRV431 Demonstrates Additional Potential Advantage in Liver Disease

Accesswire December 2, 2020

Hepion Announces Closing of Public Offering of Common Stock

Accesswire November 30, 2020

Hepion Pharmaceuticals Prices Public Offering

Accesswire November 24, 2020

Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation of Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH

Accesswire November 18, 2020

Hepion Pharmaceuticals to Participate in the Alliance Global Partners' Virtual Healthcare Symposium

Accesswire November 17, 2020

Hepion Pharmaceuticals to Present at The Liver Meeting Digital Experience(TM) 2020

Accesswire November 12, 2020